What is the best AI model for drug discovery in May 2026?

It depends on the stage. For early discovery — target identification, hypothesis generation, genomics interpretation, pathway analysis — GPT-Rosalind (OpenAI, research preview as of April 2026) is the most specialized choice, with top BixBench scores and expert-level RNA prediction. For structure prediction, AlphaFold 3 remains the standard. For general scientific reasoning, literature review, and protocol writing, Claude Opus 4.7 and GPT-5.5 lead. For multimodal molecular work and large-scale dataset analysis, Gemini 3.1 Pro is strong. Most drug-discovery teams in May 2026 use a stack of these models rather than one.

What is GPT-Rosalind and who can use it?

GPT-Rosalind is OpenAI's specialized life-sciences model, introduced in April 2026 and available as a research preview for eligible U.S. enterprise customers. Named after Rosalind Franklin, it's designed for biochemistry, drug discovery, and medicine development. It assists researchers with evidence review, hypothesis generation, experiment planning, and data analysis — particularly target discovery, target validation, genomics interpretation, and pathway analysis. Access is through ChatGPT Enterprise, Codex, and the OpenAI API, with a dedicated Life Sciences research plugin connecting to 50+ scientific data sources. Early collaborators include Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific, and Novo Nordisk.

Can I use general-purpose models like Claude Opus 4.7 for drug discovery?

Yes — and many teams do, especially for literature review, protocol drafting, hypothesis generation, and scientific writing. Claude Opus 4.7 is strong on long-context biomedical reasoning and document synthesis. GPT-5.5 is strong on multi-step scientific analysis. Gemini 3.1 Pro is competitive across the board with strong multimodal capabilities. The difference with GPT-Rosalind is specialization: it's tuned on life-sciences data, ships with a Life Sciences plugin, and achieves expert-level results on biomedical benchmarks (BixBench, RNA prediction). For pure literature and writing tasks, general models work. For target discovery and biomedical hypothesis generation, specialized models pull ahead.

How do AI models for drug discovery compare to AlphaFold 3?

AlphaFold 3 (Google DeepMind) is the specialized structure-prediction model — it predicts protein structures and protein-ligand interactions. It's not a general reasoning model and doesn't write hypotheses or analyze literature. GPT-Rosalind, Claude Opus 4.7, and GPT-5.5 are general or life-sciences-tuned reasoning models. The two categories are complementary: AlphaFold 3 for structure, reasoning models for hypothesis and analysis. A complete drug-discovery stack uses AlphaFold 3 (or equivalent) for structure plus a reasoning model for the rest of the workflow.

Quick Answer

Best AI Models for Drug Discovery (May 2026 Ranked)

Published: May 11, 2026

Best AI Models for Drug Discovery (May 2026 Ranked)

The drug-discovery AI stack matured in 2026. OpenAI’s GPT-Rosalind shipped in April, Claude Opus 4.7 reached GA, and AlphaFold 3 is the structure-prediction baseline. Here’s the ranked list of models for biotech and pharma in May 2026.

Last verified: May 11, 2026

TL;DR ranking by job

Job	Best model	Why
Target discovery & validation	GPT-Rosalind	Life-sciences-tuned, BixBench top scores
Hypothesis generation	GPT-Rosalind or Claude Opus 4.7	Specialized vs general reasoning depth
Genomics interpretation	GPT-Rosalind	Pathway analysis, RNA prediction
Protein structure prediction	AlphaFold 3	Specialized, gold standard
Literature review	Claude Opus 4.7	Long context, citation-aware
Protocol writing	GPT-5.5 or Claude Opus 4.7	Strong scientific writing
Multimodal molecular data	Gemini 3.1 Pro	Native multimodal at scale
Coding analyses (R, Python)	Claude Opus 4.7 or GPT-5.5	Top SWE-bench performance

1. GPT-Rosalind — the specialist

Why it leads early discovery.

OpenAI’s GPT-Rosalind launched in April 2026 as a research preview for eligible U.S. enterprise customers. It’s purpose-built for life sciences:

Top BixBench score — leading biomedical benchmark performance.
Expert-level RNA prediction — competitive with specialized RNA models.
Tuned for target discovery, target validation, genomics interpretation, pathway analysis.
Life Sciences plugin — connects to 50+ scientific data sources (PubMed, UniProt, ChEMBL, Ensembl, and others).
Access via ChatGPT Enterprise, Codex, OpenAI API.

Named after Rosalind Franklin (whose X-ray diffraction work was foundational to DNA structure), GPT-Rosalind is OpenAI’s deepest industry-specific push to date.

Early collaborators: Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific, Novo Nordisk.

Use it for: Reviewing biomedical evidence, generating hypotheses, designing experiments, interpreting genomics, analyzing pathways, target ID and validation.

Don’t use it for: Protein structure (use AlphaFold 3), general coding (use GPT-5.5 or Opus 4.7), non-biomedical reasoning.

2. AlphaFold 3 — the structure baseline

Why it’s still the structure standard.

Google DeepMind’s AlphaFold 3 (and its successors and competitors like RoseTTAFold, Boltz, ESMFold) remain the gold standard for protein structure prediction and protein-ligand interaction modeling.

It’s a fundamentally different category from GPT-Rosalind:

Specialized model, not a general reasoning LLM.
Predicts structure, doesn’t write analysis or hypotheses.
Used as an input to higher-level reasoning workflows.

Use it for: Protein structure, protein-protein interactions, protein-ligand binding, structure-based drug design.

Don’t use it for: Anything that needs natural-language reasoning or document synthesis.

3. Claude Opus 4.7 — best literature & long-context reasoning

Why it’s a drug-discovery favorite for non-structure work.

Claude Opus 4.7 (Anthropic, GA April 16, 2026) leads on:

Long-context reasoning — important for synthesizing literature across many papers.
Citation-aware writing — strong on protocol drafting, manuscript drafting, regulatory writing.
SWE-bench Verified at 87.6% — best-in-class for the coding side of computational biology workflows.
MCP tool use at 77.3% — strong for agentic workflows that pull from biomedical databases.

Use it for: Literature review across hundreds of papers, protocol drafting, manuscript and grant writing, bioinformatics coding, agentic workflows querying biomedical databases.

Don’t use it for: Specialized RNA or pathway tasks where GPT-Rosalind is purpose-built.

4. GPT-5.5 — strong general scientific reasoning

Why it’s competitive for biotech reasoning.

OpenAI’s GPT-5.5 (released April 23, 2026) is the strongest general-purpose model for multi-step scientific analysis, with:

High reasoning depth with the Thinking variant.
State-of-the-art Terminal-Bench 2.0 performance for shell-driven analysis pipelines.
Token efficiency — ~72% fewer output tokens than Opus 4.7 for equivalent tasks, meaning lower per-task cost on high-volume pipelines.
1M-token context holding performance past 128K.

Use it for: Multi-step computational analyses, scientific writing, hypothesis chains that need deep reasoning, cost-sensitive high-volume biomedical agent loops.

Don’t use it for: Specialized life-sciences benchmarks where GPT-Rosalind is purpose-built.

5. Gemini 3.1 Pro — strong multimodal & dataset analysis

Why it earns a spot in biotech.

Google’s Gemini 3.1 Pro is competitive across the board and especially strong on:

Native multimodal handling — images, text, structured data in one model.
Large-scale dataset analysis in Google Cloud / BigQuery workflows.
Long-context coding — 80.6% SWE-bench Verified.
Available on Vertex AI with strong enterprise compliance posture.

Use it for: Multimodal molecular data, image-heavy assays (microscopy, pathology), large-dataset bioinformatics in GCP.

Don’t use it for: Specialized biomedical benchmarks where GPT-Rosalind leads.

6. Open-weights options worth knowing

For self-hosted, regulated, or on-prem workloads where weight ownership matters:

DeepSeek V4-Pro — open weights (MIT), 1M context, strong general performance. Useful for general scientific reasoning where compliance forbids cloud-API use.
Llama 5 — strongest open-weights ecosystem for fine-tuning on proprietary biomedical data.
Qwen 3.6 — strong on code (Qwen 3 Coder variant) for computational-biology pipelines.
BioGPT successors — specialized open biomedical models, smaller but tunable.

These don’t beat the specialized leaders on benchmarks but are the only option when data residency or weight ownership is non-negotiable.

Building a drug-discovery AI stack

Most teams use a stack, not a single model. A typical stack in May 2026:

Hypothesis & target discovery      → GPT-Rosalind
Structure prediction               → AlphaFold 3 (or Boltz, RoseTTAFold)
Literature synthesis & writing     → Claude Opus 4.7
Multi-step computational analysis  → GPT-5.5 Thinking
Multimodal assay data              → Gemini 3.1 Pro
Bioinformatics coding              → Claude Opus 4.7 / GPT-5.5
Regulated / on-prem reasoning      → DeepSeek V4-Pro (open weights)

Routing logic — model router pattern — sends each request to the right specialist.

What to watch next

GPT-Rosalind GA expansion beyond U.S. enterprise research preview.
Anthropic biomedical specialization — Claude Mythos (preview) has biomedical capabilities expected.
Open biomedical models catching up on BixBench.
Multimodal AlphaFold successors — structure + reasoning in one model.

Last verified: May 11, 2026 — sources: OpenAI GPT-Rosalind announcement, Anthropic Claude Opus 4.7 release notes, OpenAI GPT-5.5 release notes, TLT AI Brief May 2026, Darwin Research analysis, Qz coverage, Manufacturing Chemist, ETedge Insights.

Best AI Models for Drug Discovery (May 2026 Ranked)

TL;DR ranking by job

1. GPT-Rosalind — the specialist

2. AlphaFold 3 — the structure baseline

3. Claude Opus 4.7 — best literature & long-context reasoning

4. GPT-5.5 — strong general scientific reasoning

5. Gemini 3.1 Pro — strong multimodal & dataset analysis

6. Open-weights options worth knowing

Building a drug-discovery AI stack

What to watch next

Related reading